Mariko Asaoka

5PUBLICATIONS
10CO-AUTHORS
Communications engineering not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 13, 2026
Correction: Tokumaru et al. High Expression of microRNA-143 Is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer. Int. J. Mol. Sci. 2020, 21, 3213.

|Jun 24, 2022
NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation.

Rongrong Wu, Arya Mariam Roy, Yoshihisa Tokumaru

|Jan 06, 2021
Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.

Mariko Asaoka, Shipra Gandhi, Takashi Ishikawa

|Oct 07, 2020
M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer.

Masanori Oshi, Yoshihisa Tokumaru, Mariko Asaoka

|Feb 07, 2020
Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate.

Hideo Takahashi, Mariko Asaoka, Li Yan

Pageof 1

Frequent Collaborators

5 joint publications

Kazuaki Takabe

3 joint publications

Yoshihisa Tokumaru

2 joint publications

Masanori Oshi

1 joint publications

Hideo Takahashi